X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) had its target price lifted by equities researchers at HC Wainwright from $3.00 to $5.00 in a research note issued on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 352.49% from the company’s […]
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Free Report) – Equities research analysts at Brookline Capital Management increased their FY2026 earnings estimates for X4 Pharmaceuticals in a research report issued to clients and investors on Monday, April 29th. Brookline Capital Management analyst L. Cann now expects that the company will earn $0.32 per share for the year, […]
(Reuters) -X4 Pharmaceuticals said on Monday the U.S. FDA has approved its therapy to treat a rare genetic immunodeficiency disease in patients 12 years of age and older, sending its shares up 16% before the bell. X4's mavorixafor, which will be sold under the brand name Xolremdi, is the first therapy to get U.S. approval specifically for the treatment of WHIM syndrome. WHIM is characterized by disorders in which the body's immune system does not function properly.
HC Wainwright reiterated their buy rating on shares of X4 Pharmaceuticals (NASDAQ:XFOR – Free Report) in a research note released on Friday, Benzinga reports. The brokerage currently has a $3.00 price objective on the stock. Separately, B. Riley lowered X4 Pharmaceuticals from a buy rating to a neutral rating and lowered their target price for […]
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Free Report) CEO Paula Ragan sold 199,531 shares of the company’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $0.73, for a total transaction of $145,657.63. Following the completion of the transaction, the chief executive officer now owns 876,347 shares […]